- Home
- OLP vs PHAR Comparison
OLP vs PHAR Comparison
Compare OLP & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLP | PHAR |
|---|---|---|
| Founded | 1982 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.2M | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OLP | PHAR |
|---|---|---|
| Price | $20.73 | $18.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 106.5K | 28.7K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 8.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.54 | 0.00 |
| Revenue | $97,423,000.00 | ★ $362,274,000.00 |
| Revenue This Year | $7.95 | $25.19 |
| Revenue Next Year | $6.06 | $4.47 |
| P/E Ratio | ★ $13.45 | $3,363.09 |
| Revenue Growth | 9.29 | ★ 26.78 |
| 52 Week Low | $19.62 | $7.50 |
| 52 Week High | $28.36 | $18.82 |
Technical Indicators
Market Signals| Indicator | OLP | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 61.38 |
| Support Level | $19.94 | $16.55 |
| Resistance Level | $21.33 | $17.37 |
| Average True Range (ATR) | 0.38 | 0.73 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 58.44 | 92.27 |
Price Performance
Historical ComparisonAbout OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.